Knowledgebase
NRG and TerThera signed an agreement for irradiation services in the High Flux Reactor in Petten, the Netherlands to produce Terbium-161. The non-carrier-added (NCA) Terbium-161 is produced by neutron irradiation of highly enriched Gadolinium-160 targets in the Dutch research reactor.
New essential analysis equipment for Quality Control has been installed in FIELD-LAB. This equipment will be used to perform measurements on isotopes, produced by FIELD-LAB in the near future, to establish if the isotope is up to GMP (Good Manufacturing Practice) standards and, consequently, can be used in patients.
Already in 2001, NRG supported the development of Peptide Receptor Radionuclide Therapy with carrier added Lutetium-177 (Lu-177 c.a.) by the supply of Lutetium-177 trichloride as a radiochemical. Nowadays, Lu-177 no carrier added is preferably used. “Lu-177 n.c.a. has a higher specific activity and thus radiolabeling efficiency, than lu-177 c.a.”, according to Marion Chomet, lead scientist at FIELD-LAB. Chomet and her colleagues are now fine-tuning and finalizing their custom made lutetium-177 n.c.a. process. But there are several challenges and practical considerations that they are facing.
It is game on for actinium-225 and lead-212. These two alpha-emitters can treat the same cancer and they are center stage in several researches around the world. However, only one can be the winner and conquer the market. What are the differences between these two powerhouses and which one is more likely to take the prize.
Kansen voor West visited FIELD-LAB in Petten last Wednesdag 9 November. Kansen voor West (Opportunities for West) is one of the larger subsidy providers of this project and every year they choose one of their projects for a workvisit.
Minister Kuipers of Health, Welfare and Sport announced today, that money has been set aside for the construction of the PALLAS-reactor in Petten, North Holland, in the coming years.
The major bottleneck for research and development of radiopharmaceuticals for targeted alpha therapy is its limited availability. The irradiation of radium-226 could be a game changer as the amounts produced using this method could fulfill the market needs for alpha-emitters. However, there are several challenges in 226Ra target preparation and further processing of irradiated targets.
During the NVNG Spring Conference of last Friday our R&D manager Karlijn van der Schilden provided insight into the current developments of NRGǀPALLAS in the field of developing new production routes for existing and new isotopes. With inextricably linked the subject of securing availability and supply.
Customer satisfaction is a core value at NRG, and therefore we are very proud to be nominated for a Customer Experience Award in the category Biggest Riser by Integron, a large research company in Rotterdam.
In order to predict the behavior of nuclear medicine in the body after administration, Ramona Bouwman, consultant radiation protection at NRG, has been developing a biokinetic model to do just that.